سعر سارانجيوت 80مجم 14 كبسولة 2025

Sarangiot 80 mg capsules (valsartan), pack of 14, by Unipharma (Egypt); an angiotensin II receptor blocker.

• Hypertension trials: viral infection (3%), fatigue (2%) and abdominal pain (2%) occurred more often than placebo; headache and dizziness were the most common reasons for discontinuation.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to any component.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Do not co-administer aliskiren with valsartan in patients with diabetes.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• BOXED WARNING - fetal toxicity: drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus; discontinue as soon as possible when pregnancy is detected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Symptomatic hypotension may occur in volume- or salt-depleted patients (e.g. on high-dose diuretics) and in heart failure or post-MI patients; correct depletion before starting.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Changes in renal function including acute renal failure can occur, particularly in patients whose renal function depends on RAS activity (e.g. renal artery stenosis, severe heart failure); monitor renal function.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Hyperkalaemia may occur; monitor serum potassium periodically.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Potassium-sparing diuretics, potassium supplements, salt substitutes and other potassium-raising drugsMay increase serum potassium; monitor potassium.DailyMed (U.S. National Library of Medicine)
• NSAIDs including selective COX-2 inhibitorsMay worsen renal function (including acute renal failure) in elderly, volume-depleted or renally impaired patients and may attenuate the antihypertensive effect; monitor renal function.DailyMed (U.S. National Library of Medicine)
• Dual RAS blockade (ACE inhibitors, other ARBs, aliskiren)Increased risk of hypotension, hyperkalaemia and renal function changes; avoid combined use in most patients.DailyMed (U.S. National Library of Medicine)
• LithiumIncreases in serum lithium and lithium toxicity reported; monitor lithium levels.DailyMed (U.S. National Library of Medicine)

• Use of RAS-acting drugs in the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death; discontinue as soon as pregnancy is detected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; present in rat milk. Breastfeeding is not recommended during treatment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Monitor blood pressure, renal function and serum potassium.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Valsartan: Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at the AT1 receptor.